Aevi Genomic Medicine (GNMX) Sees Strong Trading Volume
Aevi Genomic Medicine Inc (NASDAQ:GNMX) saw unusually-strong trading volume on Thursday . Approximately 6,247,662 shares were traded during trading, an increase of 74% from the previous session’s volume of 3,597,828 shares.The stock last traded at $0.25 and had previously closed at $0.21.
Several equities research analysts have recently commented on GNMX shares. JMP Securities lowered shares of Aevi Genomic Medicine from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 3rd. ValuEngine lowered shares of Aevi Genomic Medicine from a “hold” rating to a “sell” rating in a research report on Thursday, December 20th.
The firm has a market capitalization of $13.86 million, a PE ratio of -0.29 and a beta of 0.41.
About Aevi Genomic Medicine (NASDAQ:GNMX)
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Featured Article: Roth IRA
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.